Search

UCB SA

Suletud

160.55 0.34

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

160.55

Max

161.5

Põhinäitajad

By Trading Economics

Sissetulek

104M

Müük

127M

2.8B

P/E

Sektori keskmine

26.67

Aktsiakasum

2.09

Kasumimarginaal

3.728

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.23 upside

Turustatistika

By TradingEconomics

Turukapital

-180M

31B

Eelmine avamishind

160.21

Eelmine sulgemishind

160.55

Uudiste sentiment

By Acuity

17%

83%

UCB SA Graafik

Seotud uudised

5. dets 2023, 16:47 UTC

Market Talk

European Pharmas With New Drugs Hold Most Promise in 2024 -- Market Talk

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR  19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

1

Hoia

2

Müü

Sentiment

By Acuity

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

$

Ettevõttest UCB SA

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.